Sumitomo Chemical reported a 20% year-on-year rise in net profit to ₹214.5 crore for the quarter ended June 30, 2026 (Q1FY27), driven by operational efficiency gains and a one-time exceptional item. Revenue from operations increased modestly by 1% to ₹1,063.3 crore, while EBITDA expanded by 6% to ₹233.3 crore. The profit surge was significantly aided by an exceptional gain of ₹26.9 crore from an insurance claim related to a fire incident at the Bhavnagar plant during FY23. This filing was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The financial performance reflects strong margin expansion despite minimal top-line growth. Gross profit rose 4% to ₹416.7 crore, with gross margins improving by 111 basis points to 39.2%. Operating leverage was evident as employee expenses grew only marginally compared to revenue, allowing operating EBITDA to climb 6% to ₹233.3 crore. The EBITDA margin widened by 120 basis points to 21.9%, up from 20.7% in Q1FY26. Net profit before tax surged 20% to ₹288.2 crore, benefiting from both operational improvements and the non-recurring insurance receipt.

Financial Performance Highlights

What the Numbers Show

The divergence between flat revenue growth and double-digit profit expansion highlights the impact of the exceptional item on bottom-line figures. Excluding the ₹26.9 crore insurance gain, underlying profitability still showed strength, with EBITDA margins expanding due to controlled operating expenses. Other income also contributed positively, rising to ₹47.3 crore from ₹38.8 crore in the prior year quarter. The company noted that business seasonality makes annual monitoring more relevant than quarterly comparisons.

Board Reconstitution

Sumitomo Chemical announced a major reconstitution of its Board of Directors effective September 1, 2026. Dr. Suresh Ramachandran will be appointed as Managing Director, succeeding Chetan Shantilal Shah, whose term as Managing Director concludes on August 31, 2026. Mr. Shah will transition to a Non-Executive Non-Independent Director role and is expected to be considered for Chairman. Mukul Govindji Asher’s term as Chairman and Independent Director also ends on August 31, 2026. N. Sivaraman will be re-appointed as an Independent Director until August 31, 2029, and Anand Mohan Tiwari will join as an Independent Director until August 30, 2028.

Working Capital and Balance Sheet

Working capital dynamics shifted during the quarter. Inventory levels rose to ₹883.6 crore from ₹766.1 crore at the end of March 2026, increasing inventory days to 124 from 149. Trade receivables decreased to ₹799.8 crore from ₹735.6 crore, though receivable days improved to 68 from 83. Net working capital stood at ₹497.8 crore as of June 2026. The company maintains a debt-free balance sheet, with total assets reaching ₹4,474.2 crore at the end of FY26.

Sumitomo Chemical India Limited reported a 20.4% year-on-year increase in standalone net profit to ₹2,165.29 million for the quarter ended June 30, 2026 (Q1FY26), primarily driven by a one-time insurance claim. The agro-chemicals company’s consolidated net profit attributable to owners of the holding company rose 20.5% to ₹2,148.30 million, while revenue from operations grew marginally by 0.6% to ₹10,540.75 million on a standalone basis and remained flat at ₹10,633.46 million on a consolidated basis compared to the prior year period.

The Board of Directors approved the unaudited financial statements on July 27, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by B S R & Co. LLP, the statutory auditors. The filing includes both standalone and consolidated financial results for the quarter, prepared in accordance with Indian Accounting Standards (Ind AS).

Key Financial Highlights

The following table presents the standalone and consolidated financial performance for Q1FY26:

On an operational efficiency front, consolidated EBITDA improved to ₹2.3 billion from ₹2.2 billion in the same quarter last year, with the EBITDA margin expanding to 22% from 20.74% year-on-year. Other income contributed ₹472.84 million to the consolidated total, up from ₹387.86 million in the prior year period. Total comprehensive income for the group stood at ₹2,135.28 million.

What the Numbers Show

The profit growth was significantly boosted by exceptional items rather than core operational expansion. The company recorded a ₹268.96 million gain from an insurance claim for business interruption due to a fire incident at its Bhavnagar plant during FY23. Excluding this one-time gain, the core operational profit before tax was ₹2,643.65 million (standalone), reflecting steady underlying performance. In contrast, the prior year saw a ₹151.86 million exceptional charge related to new labour codes, highlighting the volatility from regulatory and non-operational factors.

Regulatory risks remain a key focus for the agro-chemicals segment. A Central Government notification issued in October 2022 mandates that Glyphosate, a critical product, be used only through Pest Control Operators. Industry petitions challenging this notification are pending before the Delhi High Court, with the government stating implementation will be stayed until disposal. The company operates in a single reportable segment, making it susceptible to these regulatory shifts and climatic variations affecting demand. The consolidated results include two subsidiaries: Barrix Agro Sciences Private Limited and Excel Crop Care (Africa) Limited, which is under liquidation.